Monopar Therapeutics (MNPR) Expected to Announce Earnings on Thursday

Monopar Therapeutics (NASDAQ:MNPR) is expected to be posting its quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect Monopar Therapeutics to post earnings of ($0.65) per share for the quarter.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Monday, March 31st. The company reported ($2.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($1.87). On average, analysts expect Monopar Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Monopar Therapeutics Trading Down 3.6 %

Shares of MNPR stock opened at $43.36 on Tuesday. The stock’s fifty day simple moving average is $36.16 and its 200-day simple moving average is $30.37. The company has a market capitalization of $265.15 million, a price-to-earnings ratio of -22.01 and a beta of 1.11. Monopar Therapeutics has a 1-year low of $1.72 and a 1-year high of $54.30.

Analysts Set New Price Targets

MNPR has been the subject of several analyst reports. Jones Trading reaffirmed a “hold” rating on shares of Monopar Therapeutics in a research note on Wednesday, April 2nd. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Monopar Therapeutics in a research note on Tuesday, April 1st. Finally, Piper Sandler reiterated an “overweight” rating and issued a $76.00 target price on shares of Monopar Therapeutics in a research note on Wednesday, March 19th.

Insider Buying and Selling at Monopar Therapeutics

In related news, major shareholder Tactic Pharma Llc sold 33,334 shares of the stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the completion of the sale, the insider now owns 822,255 shares in the company, valued at $28,778,925. This trade represents a 3.90 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 34.90% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.